These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 23284757)

  • 1. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
    Lucas TM; Janaka SK; Stephens EB; Johnson MC
    PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
    Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
    Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequences in gibbon ape leukemia virus envelope that confer sensitivity to HIV-1 accessory protein Vpu.
    Janaka SK; Lucas TM; Johnson MC
    J Virol; 2011 Nov; 85(22):11945-54. PubMed ID: 21917962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudotyping incompatibility between HIV-1 and gibbon ape leukemia virus Env is modulated by Vpu.
    Lucas TM; Lyddon TD; Cannon PM; Johnson MC
    J Virol; 2010 Mar; 84(6):2666-74. PubMed ID: 20042505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
    Kueck T; Neil SJ
    PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.
    Christodoulopoulos I; Droniou-Bonzom ME; Oldenburg JE; Cannon PM
    Retrovirology; 2010 Jan; 7():4. PubMed ID: 20102634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.
    Nikovics K; Dazza MC; Ekwalanga M; Mammano F; Clavel F; Saragosti S
    PLoS One; 2012; 7(4):e35411. PubMed ID: 22530020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
    Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
    Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
    Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
    Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vpu binds directly to tetherin and displaces it from nascent virions.
    McNatt MW; Zang T; Bieniasz PD
    PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.
    Lopez LA; Yang SJ; Hauser H; Exline CM; Haworth KG; Oldenburg J; Cannon PM
    J Virol; 2010 Jul; 84(14):7243-55. PubMed ID: 20444895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
    Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The viral protein U (Vpu)-interacting host protein ATP6V0C down-regulates cell-surface expression of tetherin and thereby contributes to HIV-1 release.
    Waheed AA; Swiderski M; Khan A; Gitzen A; Majadly A; Freed EO
    J Biol Chem; 2020 May; 295(21):7327-7340. PubMed ID: 32291285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
    Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.
    Petit SJ; Blondeau C; Towers GJ
    J Gen Virol; 2011 Dec; 92(Pt 12):2937-2948. PubMed ID: 21900423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.